Grifols (NASDAQ:GRFS) Stock Price Crosses Above 200 Day Moving Average - Time to Sell?

Key Points

• Grifols shares briefly crossed above their 200-day moving average of $8.03, reaching $8.03 before trading at $7.99, with 227,286 shares changing hands.
• Analyst sentiment remains cautious: two analysts rate the stock “Hold” and one rates it “Sell,” resulting in a consensus “Reduce” rating and a $10.00 target price.
• Grifols recently paid a special dividend of $0.0945 per share, while hedge funds including Brandes Investment Partners and Flat Footed increased their positions.

Shares of Grifols, S.A. (NASDAQ:GRFS - Get Free Report) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $8.03 and traded as high as $8.03. Grifols shares last traded at $7.99, with a volume of 227,286 shares traded.

Analyst Upgrades and Downgrades

GRFS has been the topic of a number of research analyst reports. Wall Street Zen lowered shares of Grifols from a "buy" rating to a "hold" rating in a research report on Monday, May 18th. Zacks Research upgraded Grifols from a "strong sell" rating to a "hold" rating in a research note on Tuesday, July 7th. Finally, Weiss Ratings raised Grifols from a "sell (d)" rating to a "sell (d+)" rating in a report on Monday, August 17th. Two equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Reduce" and a consensus target price of $10.00.

Grifols Price Performance

The firm has a market capitalization of $5.44 billion, a P/E ratio of 42.05, a PEG ratio of 0.29 and a beta of 0.66. The company has a fifty day moving average of $7.60 and a 200 day moving average of $8.03. The company has a debt-to-equity ratio of 1.10, a current ratio of 2.37 and a quick ratio of 0.81.

Grifols Dividend Announcement

The company also recently disclosed a special dividend, which was paid on Thursday, July 9th. Stockholders of record on Thursday, July 2nd were paid a $0.0945 dividend. The ex-dividend date of this dividend was Thursday, July 2nd. Grifols's dividend payout ratio is currently 47.37%.

Hedge Funds Weigh In On Grifols

A number of hedge funds have recently bought and sold shares of the company. Flat Footed LLC grew its holdings in Grifols by 26.5% during the 1st quarter. Flat Footed LLC now owns 1,372,394 shares of the biotechnology company's stock worth $11,007,000 after acquiring an additional 287,867 shares during the period. Norges Bank acquired a new stake in Grifols during the fourth quarter worth approximately $18,139,000. Quantinno Capital Management LP increased its holdings in Grifols by 42.0% in the first quarter. Quantinno Capital Management LP now owns 352,798 shares of the biotechnology company's stock worth $2,829,000 after purchasing an additional 104,418 shares in the last quarter. Brandes Investment Partners LP increased its holdings in Grifols by 6.3% in the fourth quarter. Brandes Investment Partners LP now owns 30,954,223 shares of the biotechnology company's stock worth $289,422,000 after purchasing an additional 1,838,727 shares in the last quarter. Finally, Royal Bank of Canada lifted its stake in Grifols by 15.4% in the first quarter. Royal Bank of Canada now owns 785,703 shares of the biotechnology company's stock valued at $6,301,000 after buying an additional 104,850 shares during the period.

Grifols Company Profile

Grifols, Inc NASDAQ: GRFS is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source